Angelica sinensis Can Treat LeukemiaMar. 5,2014
Angelica sinensis is one of the most commonly used clinical traditional Chinese medicines. As the main component of Angelica sinensis, Angelicapolysscharides (APS) has a great effect on promoting the platelet aggregation, antitumor effect and resistance to radiation damage. Leukemia is a type of malignant tumors of hematopoietic system. Leukemia cells have a strong ability to transmigrate. They are easy to leave the primary site, move into the blood and then infiltrate the liver, lungs and other non-hematopoietic organs. Recently, some experts found that APS together withAra-c therapy reduced the accumulation of leukemia cells within the liver, reduced the liver function damage and levels of inflammatory factors, improved antioxidant capacity of the liver tissues and thus alleviated the pathological changes of the liver.
This paper, titled by "Effect of combined administration of Angelica polysaccharide and cytarabine on liver of human leukemia NOD / SCID mouse model" and published in the 1st issue of 2014 of China Journal of Chinese Materia Medica, was jointly finished byYa-ping Wang, Jia-hong Zhu and several other experts inthe Stem Cell and Tissue Engineering Laboratory and the Tissue Embryology Laboratory of Chongqing Medical University.
Until today, non-targeted cytotoxic drugs, such as methotrexate and cytarabine, have been the main drugs to treat leukemia, which will also cause severe damage to normal tissue cells. This treatment could damage all the tissues and organs, and eventually cause the patients todie of chemotherapy-induced systemic failure.Due to special anatomy structure and physiological function of the liver, anticancer drugs are easily to cause liver damage. Studies have shown that the anti-leukemia drug stayed for a short time in the liver and the drug concentrations is relatively low, which may make the liver a sanctuary of leukemia cells.
Previous studies of this laboratory indicated that APS had a two-way adjustment effect on normal hematopoietic cells and leukemia cells. That means APS could promote proliferation and differentiation of hematopoietic stems/progenitor cells, and meanwhile inhibit the proliferation and induce the mature differentiation of leukemia cells. What’s more, APS can enhance the function of immune system and improve the ability of anti-oxidative damage of tissues. In conclusion, the APStogether with Ara-c therapy reduced the accumulation of leukemia cells within the liver, reduced the liver function damage and levels of inflammatory factors, improved antioxidant capacity of the liver tissues, alleviated the pathological changes of the liver, and thus obviously inhibited the leukemia cells.
Email: ypwangcq@ aliyun.com